Recombinant Human IBSP protein (His Tag)
Species
Human
Purity
>85 %, SDS-PAGE
Tag
His Tag
Activity
not tested
Cat no : Eg4999
Validation Data Gallery
Product Information
| Purity | >85 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Human IBSP protein Phe17-Gln317 (Accession# P21815) with a His tag at the C-terminus. |
| GeneID | 3381 |
| Accession | P21815 |
| PredictedSize | 34.6 kDa |
| SDS-PAGE | 60-90 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
Integrin-binding sialoprotein (IBSP), also known as Bone sialoprotein 2 (BSP2), is a glycoprotein that is mainly expressed in bone tissue. IBSP participates the coding of bone matrix and has a large influence on the formation, update, and repair of bones. High levels of IBSP have been found in various types of cancer, including colorectal cancer breast, esophageal squamous cell carcinoma. IBSP plays a significant role in tumor growth, invasion, and metastasis by promoting angiogenesis, cell migration and adhesion, and immune micro environment.
References:
1.Chen Y. et al. (2021) Cancer Med. 10(12):4030-4045. 2.Pan B. et al. (2023) Front Immunol. 14:1188256. 3.Ma Y. et al. (2023) Aging (Albany NY). 16(1):28-42. 4.Ding W. et al. (2024) Cancer Rep (Hoboken). 7(8):e2153.